New drug shows promise for fatty liver in early trial

NCT ID NCT04006145

First seen Feb 05, 2026 · Last updated May 10, 2026 · Updated 14 times

Summary

This study tested a drug called elobixibat in 47 adults with nonalcoholic fatty liver disease (NAFLD) or its more serious form, NASH. The goal was to see if the drug could lower bad cholesterol (LDL-C) compared to a placebo over 16 weeks. The trial also checked for side effects. This is an early-phase study to explore whether elobixibat might help manage the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAFLD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • American Research Corporation at the Texas Liver Institute

    San Antonio, Texas, 78215, United States

  • Guardian Angel Research Center, Inc.

    Tampa, Florida, 33614, United States

  • Hope Clinical Research

    Canoga Park, California, 91303, United States

  • Inland Empire Clinical Trials, LLC

    Rialto, California, 92377, United States

  • Integrity Clinical Research, LLC

    Doral, Florida, 33166, United States

  • Mercy Medical Center

    Baltimore, Maryland, 21202, United States

  • Nature Coast Clinical Research

    Inverness, Florida, 34452, United States

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado, 80907, United States

  • University of Washington

    Seattle, Washington, 98195, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23298, United States

Conditions

Explore the condition pages connected to this study.